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Background: Fiberoptic bronchoscopy (FOB) is a useful diagnosis tool in low-burden countries for patients with
suspected pulmonary tuberculosis (TB) who are smear-negative or sputum-scarce. This study sought to determine
the accuracy of the Xpert® MTB/RIF (XP) assay using FOB samples.
Methods: We retrospectively reviewed clinical, radiological, and microbiological characteristics of 175 TB-suspected
patients requiring diagnostic FOB (bronchial aspirate or bronchoalveolar lavage) with XP assay. Polymerase chain
reaction (PCR) and smear microscopy (SM) performances were first compared to culture, then to the final diagnosis,
established based on clinical or radiological evolution when cultures were negative.
Results: Of the total 162 included patients, 30 (18.5%) had a final diagnosis of pulmonary TB, with positive cultures
reported in 23. As compared to culture, sensitivity and specificity values were 80.0% and 98.6% for the XP assay,
and 25.0% and 95.8% for SM, respectively. As compared to final diagnosis, the corresponding performance values
were 60.0% and 100.0% for the XP assay, and 16.7% and 95.5% for SM, respectively. The sensitivity of the XP assay
was significantly higher than that of SM in both cases (p = 0.003 and p = 0.001). Concerning the final diagnosis, both
XP assay and culture sensitivities were similar (60% vs. 66.7%). PCR assay enabled pulmonary TB to be diagnosed
earlier in 13 more cases, compared to SM.
Conclusion: Our study has confirmed the clinical benefits provided by XP assay compared to SM for the
early diagnosis of suspected pulmonary TB cases requiring FOB, on per procedure samples, especially in a
low TB-burden country.
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Tuberculosis (TB) still constitutes a major health prob-
lem worldwide, with an 8.8% incidence and 1.3% mor-
tality rate reported in 2010 [1]. In the same year, TB
incidence was reported at 8.1 cases per 100,000 in
France [2], defining it as a low TB-burden country. It
is worth noting that 73% of TB cases were pulmonary
infections, with almost 50% producing a negative smear
microscopy (SM) [2].
By detecting active pulmonary TB early, an appropri-
ate treatment can be initiated, and disease transmission
can then be preemptively blocked. Some patients pre-
senting with active pulmonary TB may, however, exhibit
negative sputum acid-fast bacilli (AFB) smears. In devel-
oped countries, fiberoptic bronchoscopy (FOB) is con-
sidered a good option for these cases that pose a
diagnostic challenge [3], although SM is still exhibiting
low sensitivity on FOB samples, with 5-35% on bronchial
aspirates (BA) and 10-30% on bronchoalveolar lavages
(BAL) [4-9]. Furthermore, while mycobacterial culture
remains the gold standard for laboratory diagnosis of TB,
it requires 2–6 weeks to confirm a diagnosis. This results
in delays in initiating appropriate treatment while waiting
for this confirmation, except for cases where there is
strong enough clinical suspicion to initiate a presumptive
anti-TB therapy.
Several polymerase chain reaction- (PCR-) based mo-
lecular methods have recently been developed for early
TB diagnosis and rapid detection of drug resistance from
clinical specimens [10-14]. The Xpert® MTB/RIF assay
(Cepheid, Sunnyvale, CA, USA) is one of these methods,
and consists of a hemi-nested real-time PCR test that
simultaneously identifies Mycobacterium tuberculosis and
detects rifampicin resistance, as a surrogate of multidrug
resistance (MDR), directly from clinical specimens. This
assay requires less than 2 hours, and its key advantage over
other PCR methods is that it is a fully-automated process,
designed to run on the GeneXpert Dx system (Cepheid).
This system incorporates DNA extraction, often consid-
ered the critical step [15], along with real-time PCR ampli-
fication and detection in a single hands-free process, thus
acting as a real “lab-on-chip” device.
Since December 2010, WHO has recommended the
Xpert® MTB/RIF assay as a bona fide follow-on test due
to its high-quality performance [16], compared to mi-
croscopy, whenever MDR-TB or HIV are of lesser con-
cern, and especially in cases of smear-negative specimens
[17]. This conditional recommendation does, in fact, ex-
clusively concern sputum samples [17], whereas no spe-
cific recommendations for FOB samples have yet been
formulated. Finally, there have only been two recent
studies that have assessed the Xpert® MTB/RIF assay per-
formance using FOB samples for TB diagnosis in high
TB-burden countries [18,19].This study sought to evaluate the clinical value of the
Xpert® MTB/RIF assay using FOB samples for an early
diagnosis of pulmonary TB in either patients with nega-
tive sputum AFB smears or those who could not produce
an expectorated sputum sample. Patients were treated in
a French university hospital in a low TB-burden region
(5.9 cases per 100,000 in 2010).
Methods
Study population
We retrospectively reviewed the medical records of pa-
tients with suspected TB requiring a diagnostic FOB at
the Caen University Hospital (Basse-Normandie region,
North-Western France) from October 2009 to April 2013.
TB was suspected based on clinical features (e.g., cough,
hemoptysis, fever, asthenia, loss of weight, and night
sweats) or radiological features (e.g., nodule, pneumonia,
excavation, and pleurisy). All included patients either pro-
duced a negative sputum AFB SM prior to FOB procedure
or were unable to produce sputum.
Our institution, a regional center of reference for TB
diagnosis and treatment, has adopted the Xpert® MTB/
RIF assay since 2009. Patients were included in the on-
going retrospective survey if one or more Xpert® MTB/
RIF assays had been performed on their FOB samples, in
addition to SM and mycobacterial culture procedures.
Samples were excluded if culture results were unavail-
able or if the Xpert® MTB/RIF assay produced invalid re-
sults (see below). Patients who had previously received
anti-TB drugs were also excluded from analysis.
Bronchoscopic procedures
Bronchoscopy was performed using a flexible fiberscope
of either 4.9 mm (model BF-P180, Olympus Optical) or
5.1 mm in diameter (model F1-16RB, Pentax) by trained
lung specialists who first inspected the bronchial tree
and then collected BA or BAL specimens. The type of
sample was chosen at the specialist’s discretion and de-
pending on the patient’s tolerance of the procedure. The
lung section sample was generally chosen based on chest
X-ray or CT-scan abnormalities. BA samples were ob-
tained by the aspiration of pure bronchial secretions or
following the instillation of 20-50 mL isotonic saline so-
lution. For the BAL samples, 100-150 mL isotonic saline
solution was instilled by 50 mL aliquots in a lung seg-
ment, and then aspirated.
Microbiological diagnosis
All samples were digested, decontaminated by means of
N-acetyl-cysteine-2% NaOH, concentrated by centri-
fugation (at 3,500 rpm for 20 min), and tested with SM,
culture (used as the reference technique), and PCR.
For the smear test, fixed preparations were stained with
auramine and visualized under a fluorescence microscope
Table 1 Demographic, clinical, and radiological
characteristics of the 162 included patients
Characteristic N (%)











General symptomsa 73 (45.1)
Fever 43 (26.5)















Pulmonary Tuberculosis 30 (18.5)
Pleural Tuberculosis 2 (1.2)
Tuberculosis sequelae 11 (6.8)
NTMb infection 9 (5.6)
Non-mycobacterial lung infectionc 28 (17.3)
Bronchial disease exacerbation 7 (4.3)
Non-mycobacterial granulomatosis disease 7 (4.3)
Lung cancer 21 (13.0)
Otherd 23 (14.2)
No diagnosis 18 (11.1)
NA 6 (3.7)
aGeneral symptoms: asthenia and/or loss of appetite and/or loss of weight.
bNTM: Nontuberculous mycobacteria (including four M. avium, two M. xenopi,
one M. szulgai, one M. malmoense, and one other).
cIncluding 24 infectious pneumonia, two lung abscesses, and two
invasive aspergillosis.
dIncluding eight non-infectious pneumonia, five acute pulmonary edema, five
idiopathic hemoptysis, two interstitial lung disease exacerbations, one pulmonary
infarction, one intra-alveolar hemorrhage, and one inflammatory
pseudo-tumor lung.
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5 min, corresponding to 200 fields examined. Sample ali-
quots of 500 μL and 200 μL were inoculated in an MGIT
liquid medium (BD Diagnostics, Le Pont-de-Claix, France)
or on Coletsos slants (Bio-Rad, Marnes-la-Coquette,
France), respectively. Liquid cultures were automatic-
ally monitored by the BACTEC MGIT 960 system (BD
Diagnostics) for up to 6 weeks, while solid media were
studied for up to 12 weeks. Positive cultures were those
with the presence of M. tuberculosis confirmed by means
of the TB Ag MPT64 Rapid® assay (Standard Diagnostics,
Yongin, South Korea), and rifampicin susceptibility was
tested using the MGIT 960 SIRE kit (BD Diagnostics) [20].
The different species of nontuberculous mycobacteria
(NTM) were identified using the GenoType® Mycobacter-
ium CM/AS (HainLifescience, Nehren, Germany).
For the Xpert® MTB/RIF assay, a 500 μL aliquot was
poured into a single-use disposable cartridge that was
placed into the GeneXpert™ Dx module, with the results
produced in less than 2 hours. Each PCR run comprised
an internal control for sample processing (DNA extraction)
and PCR validity (presence of inhibitors), with positive and
negative controls tested every day. The system auto-
matically interpreted all results from measured fluor-
escent signals, with embedded calculation algorithms,
into the following categories: invalid, if PCR inhibitors were
detected with amplification failure; negative or positive. If
positive, the strain was categorized as susceptible or resist-
ant to rifampicin [21,22].
Pulmonary TB diagnosis
The final diagnosis of active pulmonary TB was primarily
based on the M. tuberculosis culture taken from a re-
spiratory specimen. Additional cases were classified as
definitive TB, taking into account both the clinical symp-
toms and histological/radiological findings compatible
with active pulmonary TB, as well as improvement ob-
served with anti-TB specific therapy.
Ethical considerations
According to the WHO recommendations on the Xpert®
MTB/RIF assay [16], the use of this diagnosis TB test
has been routinely implemented in our University
hospital. According to French laws, a formal agreement
from an ethics committee is not required for retrospect-
ive collection of data dealing with usual standard medical
care (ref: law n°2004-806 from August, 9th 2004, modified
by government ordinance n°2066-477 from April 26th
2006, article R1121-3, Journal officiel de la République
Française). All collected data from the charts of the
Microbiology Department were anonymous and there-
fore complied with the restrictive requirements of the
Commision Nationale de l’Informatique et des Libertés
(CNIL), the organization that ensures the application of
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was evaluated and approved by the institutional review
board of the French Society for Respiratory Medecine
(“Société de Pneumologie de Langue Française”) for ob-
servational studies (CEPRO). Finally, all patients were in-
formed of our TB diagnostic strategy, received written
information about the FOB procedure and gave there
oral consent (as recommended by the French Society of
Respiratory Diseases).
Statistical analysis
Sensitivity, specificity, positive predictive value (PPV), and
negative predictive value (NPV) were calculated, along with
the corresponding 95% confidence intervals. Sensitiv-
ity and specificity values were compared by means of
the McNemar’s test. A p-value inferior to 0.05 was
considered statistically significant. Statistical analysis




From October 2009 to April 2013, 175 consecutive pa-
tients presenting with suspected active pulmonary TB
underwent FOB with an Xpert® MTB/RIF assay using re-
spiratory samples. A total of 13 samples from 13 different
patients were excluded from our study for the following
reasons: 1) two due to PCR failure; 2) 10 due to unavailable
culture; 3) one due to recent anti-TB treatment. A total of
229 FOB samples taken from 162 patients (median age:
54 years; male/female ratio: 1.7) were included.Figure 1 Flow diagram of patients included in the study. BA: bronchia
Xpert®MTB/RIF assay; NTM: nontuberculous mycobacteria; TB: tuberculosis.The principal clinical symptoms were cough (51.9%)
and general symptoms, such as asthenia, loss of appetite,
and loss of weight for half of the patients (Table 1). The
most common lesions detected by chest imaging were
nodules (CT-scan: 60.5%) and pneumonia (CT-scan:
30.2%) (Table 1). It should be noted that 18, 9, and
80 patients had 1, 2, and 3 sputum samples, respectively,
that were collected before FOB, with the number of
Xpert® MTB/RIF assays performed on the sample ranging
from 0 to 3 for each patient (0: 110 patients; 1: 21; 2: 22;
3: 9). No sputum could be collected before the FOB pro-
cedure for 55 patients (34%) due to their inability to ex-
pectorate sputum.
Xpert® MTB/RIF assay was performed on BA (n = 48),
BAL (n = 47), or a BA/BAL mix (n = 67) (Figure 1). Out
of the 162 patients, 30 TB cases were finally diagnosed,
corresponding to a prevalence of 18.5% (Figure 1). Of
these cases, positive cultures were reported on FOB and
sputum samples for 20 and 3, respectively, including one
TB case caused by “Mycobacterium canetti”. For the
remaining seven patients, diagnosis was based on clinical
and histological/radiological features, with favorable evo-
lution under anti-TB therapy serving as confirmation.
The final diagnoses for the other patients are detailed in
Table 1.
Performances of microbiological methods
In comparison with culture used as reference, the overall
sensitivity, specificity, PPV, and NPVs for the Xpert®
MTB/RIF assay were 80.0% (95% CI: 57.8-92.5), 98.6%
(95% CI: 94.7-99.9), 88.9% (95% CI: 66.0-98.1), and 97.2%l aspirate; BAL: bronchoalveolar lavage; SM: smear microscopy; GX:
Table 3 Gain in early pulmonary tuberculosis diagnosis
with the Xpert® MTB/RIF assay
N = 162 patients TB + (N = 30 patients) TB- (N = 132 patients)
Xpert®MTB/RIF (XP)+ 18 0
Smear microscopy (SM) + 5 6 (=6 NTMa)
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for SM were recorded as 25.0% (95% CI: 10.8-47.3), 95.8%
(95% CI: 90.9-98.3), 45.5% (95% CI: 21.3-72.0), and 90.1%
(95% CI: 84.2-94.0), respectively (Table 2). It is inter-
esting to note that the sensitivity of the Xpert® MTB/
RIF assay was found to be significantly higher than that of
SM (p = 0.003; Table 2).
When considered relative to the final diagnosis, the
performances of both sensitivity (60%; 95% CI: 42.3-
75.4) and specificity (100%; 95% CI: 96.6-100.0) of the
Xpert® MTB/RIF assay were also shown to be signifi-
cantly higher than those of SM (16.7%; 95% CI: 6.9
to 34.0; 95.5%; 95% CI: 90.2 to 98.1) (p = 0.001 and
p = 0.041) (Table 2). PPV and NPV were 100.0% (95%
CI: 79.3-100.0) and 91.7% (95% CI: 85.9-95.3) for the
Xpert® MTB/RIF assay, respectively, while these values
were measured at 45.5% (95% CI: 21.3-72.0) and 83.4%
(95% CI: 76.6-88.6) for SM, respectively. It is worth not-
ing that all six samples with a positive SM and a negative
PCR assay were seen to grow an NTM species. Regarding
the final diagnosis, no significant difference was observed
between Xpert® MTB/RIF assay and culture sensitivities
(60%; 95% CI: 42.3-75.4 vs. 66.7%; 95% CI: 48.7-80.9;
p = 0.683).
The Xpert® MTB/RIF assay also enabled earlier TB
diagnosis and treatment for 13 more patients than was
possible with SM (Table 3). In addition, the Xpert® MTB/
RIF assay led to the early detection of one MDR-TB case
in our series, which was subsequently confirmed using
phenotypic tests.Table 2 Performances of the Xpert®MTB/RIF assay, smear mic
of pulmonary tuberculosis
Performances relative to culture
Sensitivity% Specificity%
(95% CI) n (95% CI) n
Xpert® MTB/RIF assay 80.0 98.6
(57.8-92.5) (94.7-99.9)
16/20 140/142





ap-values were calculated using the McNemar’s test.
bp-value between Xpert®MTB/RIFassay vs. smear microscopy.
cp-value between Xpert®MTB/RIFassay vs. culture.
dp-value between culture vs. smear microscopy.Discussion
FOB constitutes an interesting alternative for TB diagno-
sis in smear-negative or sputum-scarce patients, espe-
cially in developed countries where this procedure is
widely available. Given that WHO recommendations on
the Xpert® MTB/RIF assay only pertain to sputum sam-
ples [17], further investigation must be conducted re-
garding the use of this PCR on FOB samples. To the
best of our knowledge, there has been no publication
specifically describing the clinical interest and accuracy
of the Xpert® MTB/RIF assay using FOB samples for TB
diagnosis in a low-prevalence country.
Our study produced results in line with previous re-
ports on respiratory samples [16,23-31], demonstrating
that the Xpert® MTB/RIF assay significantly outperformed
SM on FOB samples (sensitivities: 80.0% vs. 25.0%;
p = 0.003) in a low TB-prevalence area. The sensitivity of
the PCR assay was found to be lower when it was calcu-
lated relative to the final diagnosis, yet still remainedroscopy, and culture using FOB samples for the diagnosis
Performances relative to final diagnosis
Sensitivity% Specificity%
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vs. 16.7%; p = 0.001). Our findings revealed similar per-
formances to those reported by two recently published
studies, which had previously explored the clinical use-
fulness of the Xpert® MTB/RIF assay on FOB samples, al-
though this was conducted in high TB-prevalence areas
[18,19]. In the Lee et al. retrospective study, 132 patients
were recruited in a single South-Korean center. The
study reported sensitivity and specificity values (relative
to the culture) of 81.6% and 100.0% for the Xpert® MTB/
RIF assay, compared to 13.2% and 98.8% for SM, re-
spectively [18]. Theron et al. prospectively included
154 patients in a South-African single-center study and
specifically analyzed BAL samples. The resulting sensitivity
and specificity values compared to the culture were 92.6%
and 96.0% for the Xpert® MTB/RIF assay, and 57.7% and
99.3% for SM, respectively [19].
We can therefore confirm that for suspected TB re-
quiring bronchoscopic procedure, the Xpert® MTB/RIF
assay is a potential alternative to SM using FOB samples.
In our study, PCR allowed for early pulmonary TB diag-
nosis to be established, enabling appropriate treatment
to be started early for 13 more patients as compared to
SM (72%) (p < 0.001; Table 3). In these patients, the de-
finitive TB diagnosis was secondarily confirmed either
by culture or clinical evolution under specific antimicro-
bial therapy. These findings were similar to those of the
Theron et al. study (>80%) [19], and are of particular
significance in a low TB-incidence area, where there is a
higher proportion of alternative diagnosis, such as lung
cancer or pyogenic bacterial pneumonia.
Our study objectives did not include assessing the
value of the GeneXpert® assay in detecting rifampicin
resistance on FOB samples, since the incidence of such re-
sistance was expected to be low, as seen in previous studies
[18,19]. The unique case of MDR-TB was, however, unam-
biguously detected, and all PCR results were corroborated
by those that were phenotypically determined.
Our study presented some limitations. Firstly, this
was a retrospective study, despite all Xpert® MTB/RIF
assays being performed on fresh FOB samples. Sec-
ondly, it was a single-center study. Finally the PCR
assays were not systematically performed on the same
FOB sample for all patients (BA or BAL). A prospect-
ive study should be designed with systematized and
parallel FOB sampling (BA, BAL). This would provide
a more proficient way of testing the Xpert® MTB/RIF
assay in different types of per-endoscopic respiratory
samples, an endpoint that we were unable to analyze
due to our retrospective design. Cost-effectiveness studies
should also be conducted in order to specify the rational
use of the Xpert® MTB/RIF assay on FOB samples in novel
diagnostic algorithms, including this PCR assay in well-
resourced countries.Conclusion
In summary, our study confirms the clinical usefulness
of the Xpert® MTB/RIF assay, compared to SM, for the
early diagnosis of suspected pulmonary TB requiring
FOB, performed on per procedure samples. This is a
reproducible commercial assay, and should especially
be considered as a relevant option in low TB-burden
countries.
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